Outpace Bio is a venture-backed biotechnology company building a platform to create next-generation smart cell therapies. Our world-class scientific team is developing cell therapies that intervene in complex biology in ways that small molecules and biologics cannot. Our rich platform combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. We create mechanism-driven solutions tailor-made to dramatically improve efficacy and safety. Our partnership business model will accelerate the clinical validation of our platform and the development of truly curative therapies. We value teamwork, creativity, integrity, rigor, and passion for science.
At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
Employees: 11-50
Total raised: $174M
Founded date: 2020
Investors 7
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.08.2024 | Series B | $144M | - |
| 05.04.2021 | Series A | $30M | - |
Mentions in press and media 10
| Date | Title | Description |
| 15.08.2024 | Outpace Bio: Cell Therapy Company Raises $144 Million (Series B) | Outpace Bio, a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors, announced that it had raised $144 million in oversubscribed Series B financin... |
| 03.08.2024 | Outpace Bio: A New Dawn in Cancer Treatment with AI-Powered Cell Therapies | In the realm of cancer treatment, innovation is the lifeblood. Outpace Bio is injecting fresh vigor into this field with its recent $144 million Series B financing. This funding, led by RA Capital Management, is a beacon of hope for patient... |
| 01.08.2024 | Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development | Seattle, WA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- – Financing syndicate led by RA Capital Management with significant support from a world-class group of existing and new healthcare investors – Proceeds to advance multiple programmed T cell pr... |
| 01.08.2024 | Outpace Bio Secures $144M for AI-Powered Cell Therapy Platform | What You Should Know: – Outpace Bio, a pioneering cell therapy company raises $144M in oversubscribed Series B financing round led by RA Capital Management with participation from both new and existing investors, including Qatar Investment ... |
| 10.07.2023 | How AI is changing the way scientists engineer drugs, biosensors, enzymes and more | RF Diffusion, a deep learning tool, was prompted to generate a new protein (orange) that binds to the insulin receptor (blue). The tool is now being used by biopharma companies to help design proteins for a variety of uses. Click here for v... |
| 05.04.2021 | Outpace Bio Raises $30 Million To Design Next Generation Cell Therapies | Marc Lajoie, CEO of OutpaceOutpace Bio |
| 31.03.2021 | Seattle biotech startup Outpace Bio raises $30M to fight cancer with custom-designed proteins | Outpace Bio CEO (Outpace Photo) New funding: Outpace Bio raised a $30 million Series A investment round to design custom cell and gene-based therapies. The science: Founded in November, the Seattle startup is developing software and hardwar... |
| 31.03.2021 | Outpace Bio Raises $30M in Series A Funding | Outpace Bio, a Seattle, WA-based biotechnology company building a platform to create next-generation smart cell therapies, closed a $30m Series A financing round. The round was led by Artis Ventures and Lyell Immunopharma, Inc., with partic... |
| - | Outpace Bio | “Outpace | Home” |
| - | Outpace Bio | “Home | Outpace” |